系统性红斑狼疮相关动脉粥样硬化研究进展

doi:10.3969/j.issn.1004-583X.2024.11.015

摘要/Abstract

摘要：

系统性红斑狼疮(systemic lupus erythematosus, SLE)患者动脉粥样硬化和心血管疾病风险增加。炎症在SLE相关动脉粥样硬化的病理机制中起主导作用,控制炎症反应至关重要。SLE相关动脉粥样硬化的危险因素包括疾病活动、抗磷脂抗体等各种自身抗体和新兴生物标志物。目前,SLE相关动脉粥样硬化的治疗方案包括传统抗动脉粥样硬化药物和针对SLE的治疗药物。本文将对SLE相关动脉粥样硬化的发病机制、危险因素和治疗的最新研究进展进行综述,旨在为临床提供参考。

中图分类号:

王玉伟, 金迪, 付永兴, 刘志刚. 系统性红斑狼疮相关动脉粥样硬化研究进展[J]. 临床荟萃, 2024, 39(11): 1052-1056.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2024.11.015

https://huicui.hebmu.edu.cn/CN/Y2024/V39/I11/1052

参考文献 35

[1]	Mahtta D, Gupta A, Ramsey DJ, et al. Autoimmune rheumatic diseases and premature atherosclerotic cardiovascular disease: An analysis from the VITAL Registry[J]. Am J Med, 2020, 133(12):1424-1432. doi: 10.1016/j.amjmed.2020.05.026 pmid: 32598903
[2]	Petri MA, Barr E, Magder LS. Development of a systemic lupus erythematosus cardiovascular risk equation[J]. Lupus Sci Med, 2019, 6(1):e000346.
[3]	Kurmann RD, Mankad R. Atherosclerotic heart disease in women with autoimmune rheumatologic inflammatory conditions[J]. Can J Cardiol, 2018, 34(4):381-389. doi: S0828-282X(18)30018-7 pmid: 29571422
[4]	Nikpour M, Urowitz MB, Gladman DD. Premature atherosclerosis in systemic lupus erythematosus[J]. Rheum Dis Clin North Am, 2005, 31(2):329-354.
[5]	Katz G, Smilowitz NR, Blazer A, et al. Systemic lupus erythematosus and increased prevalence of atherosclerotic cardiovascular disease in hospitalized patients[J]. Mayo Clin Proc, 2019, 94(8):1436-1443. doi: S0025-6196(19)30216-2 pmid: 31303426
[6]	Mendoza-Pinto C, Rojas-Villarraga A, Molano-González N, et al. Endothelial dysfunction and arterial stiffness in patients with systemic lupus erythematosus: A systematic review and meta-analysis[J]. Atherosclerosis, 2020, 297:55-63. doi: S0021-9150(20)30066-6 pmid: 32078830
[7]	Sciatti E, Cavazzana I, Vizzardi E, et al. Systemic lupus erythematosus and endothelial dysfunction: A close relationship[J]. Curr Rheumatol Rev, 2019, 15(3):177-188. doi: 10.2174/1573397115666181126105318 pmid: 30474532
[8]	Piranavan P, Perl A. Management of cardiovascular disease in patients with systemic lupus erythematosus[J]. Expert Opin Pharmacother, 2020, 21(13):1617-1628. doi: 10.1080/14656566.2020.1770227 pmid: 32511034
[9]	Ajeganova S, Gustafsson T, Lindberg L, et al. Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients[J]. Lupus Sci Med, 2020, 7(1):e000362.
[10]	陆玉琴, 赵信科, 冯明霞, 等. 高血压患者血清MMP-2, TIMP-2, Hcy, UA水平与颈动脉硬化的相关性[J]. 临床荟萃, 2020, 35(7):595-598.
[11]	Knight JS, Subramanian V, O’Dell AA, et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice[J]. Ann Rheum Dis, 2015, 74(12):2199-2206. doi: 10.1136/annrheumdis-2014-205365 pmid: 25104775
[12]	Teixeira V, Tam LS. Novel insights in systemic lupus erythematosus and atherosclerosis[J]. Front Med (Lausanne), 2018, 4:262.
[13]	Polytarchou K, Varvarousis D, Manolis AS, et al. Cardiovascular disease in antiphospholipid syndrome[J]. Curr Vasc Pharmacol, 2020, 18(6):538-548. doi: 10.2174/1570161117666190830101341 pmid: 31530257
[14]	Hedar AM, Stradner MH, Roessler A, et al. Autoimmune rheumatic diseases and vascular function: The concept of autoimmune atherosclerosis[J]. J Clin Med, 2021, 10(19):4427.
[15]	Medeiros PBS, Salomão RG, Teixeira SR, et al. Disease activity index is associated with subclinical atherosclerosis in childhood-onset systemic lupus erythematosus[J]. Pediatr Rheumatol Online J, 2021, 19(1):35. doi: 10.1186/s12969-021-00513-5 pmid: 33743717
[16]	Ajeganova S, Hafström I, Frostegård J. Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: A case-control study over 10 years[J]. Lupus Sci Med, 2021, 8(1):e000454.
[17]	Ganjali S, Shirmohammadi L, Read MI, et al. High-density lipoprotein functionality in systemic lupus erythematosus[J]. Semin Arthritis Rheum, 2020, 50(4):769-775.
[18]	王贞, 薛原, 林珺芳, 等. 高级氧化蛋白产物在系统性红斑狼疮早发动脉粥样硬化中的临床意义[J]. 中华风湿病学杂志, 2010, 14(6):404-407.
[19]	Giannelou M, Skarlis C, Stamouli A, et al. Atherosclerosis in SLE: A potential role for serum parathormone levels[J]. Lupus Sci Med, 2020, 7(1):e000393.
[20]	Sagar D, Gaddipati R, Ongstad EL, et al. LOX-1: A potential driver of cardiovascular risk in SLE patients[J]. PLoS One, 2020, 15(3):e0229184.
[21]	Mok CC, Wong CK, To CH, et al. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double-blind, placebo-controlled trial[J]. Arthritis Care Res (Hoboken), 2011, 63(6):875-883. doi: 10.1002/acr.20440 pmid: 21309005
[22]	Castejon R, Castañeda A, Sollet A, et al. Short-term atorvastatin therapy improves arterial stiffness of middle-aged systemic lupus erythematosus patients with pathological pulse wave velocity[J]. Lupus, 2016, 26(4):355-364.
[23]	Petri MA, Kiani AN, Post W, et al. Lupus atherosclerosis prevention study (LAPS)[J]. Ann Rheum Dis, 2011, 70(5):760-765. doi: 10.1136/ard.2010.136762 pmid: 21177297
[24]	Reiss AB, Arain HA, Kasselman LJ, et al. Human lupus plasma pro-atherogenic effects on cultured macrophages are not mitigated by statin therapy: A mechanistic LAPS substudy[J]. Medicina (Kaunas), 2019, 55(9):514.
[25]	Tselios K, Gladman DD, Su J, et al. Does renin-angiotensin system blockade protect lupus nephritis patients from atherosclerotic cardiovascular events? A case-control study[J]. Arthritis Care Res (Hoboken), 2016, 68(10):1497-1504. doi: 10.1002/acr.22857 pmid: 26866934
[26]	Kostopoulou M, Nikolopoulos D, Parodis I, et al. Cardiovascular disease in systemic lupus erythematosus: Recent data on epidemiology, risk factors and prevention[J]. Curr Vasc Pharmacol, 2020, 18(6):549-565. doi: 10.2174/1570161118666191227101636 pmid: 31880245
[27]	Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus[J]. Am J Epidemiol, 2012, 176(8):708-719. doi: 10.1093/aje/kws130 pmid: 23024137
[28]	Virdis A, Tani C, Duranti E, et al. Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus[J]. Arthritis Res Ther, 2015, 17(1):277.
[29]	Fasano S, Pierro L, Pantano I, et al. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus[J]. J Rheumatol, 2017, 44(7):1032-1038. doi: 10.3899/jrheum.161351 pmid: 28507183
[30]	Leuven SIV, Wijk DFV, Volger OL, et al. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis[J]. Atherosclerosis, 2010, 211(1):231-236. doi: 10.1016/j.atherosclerosis.2010.01.043 pmid: 20202636
[31]	Kiani AN, Magder LS, Petri M. Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years[J]. Rheumatol Int, 2012, 32(9):2701-2705. doi: 10.1007/s00296-011-2048-y pmid: 21792642
[32]	Roldan C, Joson J, Qualls C, et al. Premature aortic stiffness in systemic lupus erythematosus by transesophageal echocardiography[J]. Lupus, 2010, 19(14):1599-1605. doi: 10.1177/0961203310377088 pmid: 20813797
[33]	Oryoji K, Kiyohara C, Horiuchi T, et al. Reduced carotid intima-media thickness in systemic lupus erythematosus patients treated with cyclosporine A[J]. Mod Rheumatol, 2014, 24(1):86-92. doi: 10.3109/14397595.2013.852838 pmid: 24261763
[34]	Koulouri V, Koutsilieris M, Mavragani CP, et al. B cells and atherosclerosis in systemic lupus erythematosus[J]. Expert Rev Clin Immunol, 2019, 15(4):417-429.
[35]	陈瞿, 葛风梅, 李昭, 等. 托法替布在系统性红斑狼疮小鼠早期动脉粥样硬化中的作用探讨[J]. 中华风湿病学杂志, 2024, 28(2):106-112.

系统性红斑狼疮相关动脉粥样硬化研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 35

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张中楼, 崔坤, 孟晋启. 运动保护心血管系统的研究进展[J]. 临床荟萃, 2024, 39(9): 855-860.
[2]	马剑楠, 陶杰, 桑大森, 吴寿岭, 张旗. 尿转铁蛋白与2型糖尿病人群新发心血管疾病的关系[J]. 临床荟萃, 2024, 39(8): 700-705.
[3]	庞樱容, 孙欣. sST2在心血管疾病中作用的研究进展[J]. 临床荟萃, 2024, 39(5): 460-465.
[4]	顾天舒, 梁雪, 蔡嘉庚, 李广平. m6A RNA甲基化修饰在心血管疾病中的进展[J]. 临床荟萃, 2023, 38(8): 743-748.
[5]	徐阳, 薛凌. H型高血压合并2型糖尿病患者轻度认知功能障碍的影响因素[J]. 临床荟萃, 2023, 38(10): 887-892.
[6]	王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.
[7]	张怡, 崔晓冉, 杨晓红. 单核细胞/高密度脂蛋白胆固醇比值在心血管疾病中研究进展[J]. 临床荟萃, 2022, 37(6): 551-555.
[8]	张磊, 娄海东, 智昱, 亓树莹. PCSK9抑制剂对动脉粥样硬化性心血管疾病有效性及安全性的meta分析[J]. 临床荟萃, 2022, 37(12): 1074-1080.
[9]	贺容容, 李锦霞, 任俊豪, 孙辉. 单核细胞与高密度脂蛋白胆固醇比值在动脉粥样硬化性疾病中的研究进展[J]. 临床荟萃, 2022, 37(10): 950-952.
[10]	文洁. 血浆致动脉粥样硬化指数与非酒精性脂肪性肝病的相关性[J]. 临床荟萃, 2022, 37(1): 35-38.
[11]	杨瑞, 刘宇宏. 类风湿关节炎患者血脂水平与心血管疾病风险相关研究进展[J]. 临床荟萃, 2022, 37(1): 92-96.
[12]	叶蒙蒙, 李旎, 徐国栋, 邵国丰. miR-361在心血管疾病的研究进展[J]. 临床荟萃, 2021, 36(9): 843-849.
[13]	卢昊阳, 卢家忠, 韩明锋, 吕新才, 张标, 戎成振, 贾蕾蕾, 潘强强, 马蕾蕾, 赵韧. 新型冠状病毒肺炎合并心血管疾病的临床治疗观察[J]. 临床荟萃, 2021, 36(3): 203-207.
[14]	刘宇博, 冯平勇, 杨海骁, 孙婕, 张天资. 高分辨磁共振血管壁成像在颅内动脉粥样硬化性缺血性卒中的研究进展[J]. 临床荟萃, 2021, 36(12): 1148-1152.
[15]	王超, 万多, 李卅立, 王曦. 颈动脉多普勒超声对慢性肾病患者动脉粥样硬化程度及血流动力学的评估价值[J]. 临床荟萃, 2021, 36(11): 1009-1012.